Impact of combination of local carbonic anhydrase inhibitors and beta-blockers on intraocular pressure, visual functions and eye hemodynamics in primary open-angle glaucoma
https://doi.org/10.21516/2072-0076-2021-14-2-96-102
Abstract
Drug treatment optimization in primary open-angle glaucoma (POAG) is a topical issue of ophthalmology in recent decades. The review focuses on the choice of local hypotensive therapy and the effectiveness of a fixed combination (FC) of dorzolamide / timolol in glaucoma treatment. Since decreased perfusion eye pressure and disturbed regulation of local hemodynamics affect the development and progression of glaucomatous optical neuropathy, the use of anti-glaucomatous drugs or other hypotensive agents requires taking account of their effect on intraocular pressure (IOP), visual functions, and ocular blood flow. Most studies show that the hypotensive and hemodynamic effects of dorzolamide/timolol FC contribute to the preservation of visual fields in POAG patients by reducing significant risk factors for POAG progression, such as increased IOP and blood flow deficiency in the retinal and choroidal vessels. Improved hemodynamic parametersdue to local hypotensive treatment can be considered as basis for visual function stabilization, especially in long-term chronic courses of the disease.
About the Authors
T. N. Malishevskaya
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Tatiana N. Malishevskaya— Dr. of Med. Sci., head of the department of analytics
T. N. Kiseleva
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Tatiana N. Kiseleva — Dr. of Med. Sci., professor, head of ultrasound diagnostic department
A. S. Vlasova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Anastasia S. Vlasova— assistant professor, chair of ophthalmology and optometry
E. K. Eliseeva
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Elena K. Eliseeva— Cand. of Med. Sci., researcher of ultrasound diagnostic department
References
1. Delgado М.F., Abdelrahman A.M., Terahi M., et al.Management of glaucoma in developing countries: challenges and opportunities for improvement. Clinicoecon. Outcom. Res. 2019; 11: 591–604. doi:10.2147 / CEOR.S218277
2. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006; 90: 262–7. doi:10.1136/bjo.2005.081224
3. Tham Y.C., Li X., Wong T.Y., et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and metaanalysis. Ophthalmology. 2014; 121 (11): 2081–90. doi:10.1016/j.ophtha. 2014.05.013
4. Varma R., Lee P.P., Goldberg I., Kotak S. An assessment of the health and economic burdens of glaucoma. Am. J. Ophthalmol. 2011; 152 (4): 515–22. doi:10.1016/j.ajo.2011.06.004
5. Leite M.T., Sakata L.M., Medeiros F.A.Managing glaucoma in developing countries. Arq. Bras. Oftalmal. 2011; 74 (2): 83–4. doi:10.1590/S0004-27492011000200001
6. Chen P.P. Risk and risk factors for blindness from glaucoma. Curr. Opin. Ophthalmol. 2004; 15 (2): 107–11. doi:10.1097/00055735- 200404000-00009
7. Neroev V.V., Kiseleva O.A., Bessmertny A.M. The main results of a multicenter study of epidemiological features of primary open-angle glaucoma in the Russian Federation. Russian ophthalmological journal. 2013; 6 (3): 4–7 (in Russian)].
8. Neroev V.V., Mikhaylova L.A.Ophthalmological morbidity in Russia. In: Avetisov S.E., Egorov E.А., Moshetova L.K., Takhchidi Kh.P., eds. Ophthalmology. National Guidelines. Moscow: Geotar-Media; 2018: 15–9 (in Russian)].
9. Glaucoma: diagnosis and management. Methods, evidence and recommendations. London: NICE; 2017. Avaible at: https://www.nice.org.uk/guidance/ng81
10. Egorov E.А., Erichev V.P., eds.National Glaucoma Guidelines for Practicioners. 4th Edition, corrected. Moscow: Geotar-Media; 2019 (in Russian)].
11. European Glaucoma Society Terminology and Guidelines for Glaucoma (4th Edition). Savona: PubliComm; 2014.
12. Kalouda P., Keskini C., Anastasopoulos E., Topouzis F.Achievements and limits of current medical therapy of glaucoma. Dev. Ophthalmol. 2017; 59: 1–14. doi:10.1159/000458482
13. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7:the relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 2000; 130 (4): 429–40. doi: 10.1016 / s0002-9394 (00) 00538-9
14. Leske M.C., Heijl A., Hyman L., et al. for the EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114 (11): 1965–72. doi:10.1016/j.ophtha.2007.03.016
15. Gordon M.O., Beiser J.A., Brandt D., et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open angle glaucoma. Arch. Ophthalmology. 2002; 120: 714–20; discussion 829-30. doi:10.1001 / archopht.120.6.714
16. Federal Clinical Gidelines “Diagnostics and treatment of prtimary open-angle glaucoma”. Available at: https://www.kormed.ru/articles/normativno-pravovye-akty/klinicheskie-rekomendatsii-protokolylecheniya/klinicheskie-rekomendatsii-protokoly-lecheniya-po-oftalmologii/pdf/glaukoma.pdf (in Russian)].
17. Drance S., Anderson D., Schulzer M. Risk factors for progression of visual field abnormalities in normal tension glaucoma. Am. J. Ophthalmol. 2001; 131: 699–708. doi:10.1016/S0002-9394(01)00964-3
18. Konstas A.G., Papapanos P., Tersis I., et al.Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005 % versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003; 110: 1357–60. doi:10.1016/S0161-6420(03)00404-4
19. Hayreh S.S. Progress in the understanding of the vascular etiology of glaucoma. Curr. Opin. Ophthalmol. 1994; 5: 26–35.
20. Chung H.S., Harris A., Kagemann L., et al.Peripapillary retinal blood flow in normal tension glaucoma. Br. J. Ophthalmol. 1999; 83: 466–9. doi:10.1136/bjo.83.4.466
21. Grunvald J.E., Piltz J., Hariprasad S.M., Dupont J., Maguire M.G. Optic nerve blood flow in glaucoma: effect of systemic hypertension. Am. J. Ophthalmol. 1999; 127: 516–22. doi:10.1016/S0002-9394(99) 00028-8
22. Harris A., Sergott R.C., Spaeth G.L., et al.Color Doppler analysis of ocular vessel blood velocity in normal-tension glaucoma. Am. J. Ophthalmol. 1994; 15(118): 642–9. doi:10.1016/S0002-9394(14)76579-1
23. Rankin S.A., Walman B.E., Bukley A.R., Drance S.W.Color Doppler imaging and analysis of the optic nerve vasculature in glaucoma. Am. J. Ophthalmol. 1994; 119 (6): 685–93. doi:10.1016/S0002-9394(14)72771-0
24. Satilmis M., Orgul S., Doubler B., et al.Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am. J. Ophthalmol. 2003; 135: 664–9. doi:10.1016/S0002-9394(14)72771-0
25. Harris A., Jonescu-Cuypers C.P. The impact of glaucoma medication on parameters of ocular perfusion. Current Opinion in Ophthalmology. 2001;12 (2): 131–7. doi:10.1097 / 00055735-200104000-00009
26. Costa V.P., Harris A., Stefansson E., et al.The effects of antiglaucoma and systemic medications on ocular blood flow. Prog. Retin. Eye Res. 2003; 22 (6): 769–805. doi:10.1016/S1350-9462(03)00064-8
27. Martínez А., Manuel S.A.Comparison of the Long-Term effects of Dorzolamide 2 % and Brinzolamide 1 %, each added to Timolol 0.5 %, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. Journ. of Ocular Pharmacology and Therapeutics. 2009; 25 (3): 239–48. doi:10.1089/jop.2008.0114
28. Barnes G.E., Li B., Dean T., et al.Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. Surv. Ophthalmol. 2000; 44: 131–40. doi:10.1016/S0039-6257(99)00124-1
29. Becker B. Decrease in intraocular pressure in a man by a carbonic anhydrase inhibitor, Diamox. Am. J. Ophthalmol. 1954; 37 (1): 13–5. doi:10.1016/0002-9394(54)92027-9
30. Dobbs P.C., Epstein D.L., Anderson P.J. Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes. Invest. Ophthalmol. Vis. Sci. 1979; 18 (8): 867–70. doi:10.1073/pnas.88.7.2716
31. Hageman G.S., Zhu X.L., Waheed A., Sly W.S. Localization of carbonic anhydrase IV in a specific capillary bed of the human eye. Proc. Natl. Acad. Sci. 1991; 88 (7): 2716–20. doi:10.1073/pnas.88.7.2716
32. Macknight A.D., McLaughlin C.W., Peart D,. et al. Formation of the aqueous humor. Clin. Exp. Pharmacol. Physiol. 2000; 27 (1–2): 100–6. doi: 10.1046/j.1440-1681. 2000. 03208.x
33. Carprioli J. The ciliary epithelia and aqueous humor. In: Moses R., ed. In: Adlers Physiology of the Eye. Madrid; 1992: 228–47.
34. Wang R.F., Serle J.B., Podos S.M., Surgure M.F. MK-507 (l-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch. Ophthalmol. 1991; 109 (7): 1297–9. doi:10.1001/archopht.1991.01080090123036
35. Yamazaki Y., Miyamoto S., Sawa M.Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn. J. Ophthalmol.1994; 38 (1): 92–6.
36. Sugrue M.F., Harris A., Adamsons I.Dorzolamide hydrochloride: a topically active, carbonic anhydrase inhibitor for the treatment of glaucoma. Drugs Today. 1997; 33 (5): 283–98. doi:10.1358/dot.1997.33.5.430476
37. Stams T., Chen Y., Boriack-Sjodin P.A., et al.Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexes with brinzolamide: molecular basis of isoenzyme-drug discrimination. Protein Sci. 1998; 7 (3): 556–63. doi:10.1002/pro.5560070303
38. Sugrue M.F.Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Progr.Retin. Eye Res. 2000; 19 (1): 87–112. doi:10.1016/S1350-9462(99)00006-3
39. Louis DeSantis. Preclinical Overview of Brinzolamid. Surv. Ophthalmol. 2000; 4 (2): 119–30. doi:10.1016/S0039-6257(99)00108-3
40. Adamsons I.A., Polis A.B., Ostrov C.S., et al. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. J. Glaucoma. 1998; 7 (6): 395–401.
41. Boyle J., Ghosh K., Gieser D., Adamsons I. A randomized trial comparing the dorzolamide–timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide–Timolol Study Group. Ophthalmology. 1998; 105 (10): 1945–51. doi: 10.1016/S0161-6420(98)91046-6
42. Clineschmidt C., Williams R., Snyder E. Adamsons I.A.A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide–timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide–Timolol Combination Study Group. Ophthalmology. 1998; 105 (10): 1952–59. doi: 10.1016/S0161-6420(98)91047-8
43. March W., Ochsner K. The longterm safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-term Therapy Study Group. Am. J. Ophthalmol. 2000; 129 (2): 136–43. doi: 10.1016/S0002-9394(99)00343-8
44. Shall K.The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Surv. Ophthalmol. 2000; 44: 155–62. doi:10.1016/S0039-6257(99)00107-1
45. Assessment report for Azarga International Nonproprietary Name: brinzolamide/timolol Procedure No. EMEA/H/C/000960 Avaible at: https://www.ema.europa.eu/en/documents/assessment-report/azarga-epar-publicassessment-report_en.pdf
46. Hartleben-Matkin C., Prada D., Mancilla-Vences R.A4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG. J. Ophthalmol. 2014; 7 (2): 330–34. doi:10.3980/j.issn.2222-3959.2014.02.25
47. Martinez A., Sanchez M.Predictive value of color Doppler imaging in a prospective study of visual field progression in primary open-angle glaucoma. Acta Ophthalmol. Scand. 2005; 83: 716–23. doi:10.1111/j.1600-0420.2005.00567.x
48. Martinez A., Sanchez M. A comparison of the effects of 0.005 % latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr. Med. Res. Opin. 2006; 22 (1): 67–73. doi:1185/030079906X80215
49. Martinez A., Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and progression of visual field damage in patients with primary open-angle glaucoma: a single-centre, 4-year, open-label study. Clin. Ther. 2008; 30 (6): 1120–34. doi:10.1016/j.clinthera.2008.06.006
50. Avunduk A.M., Sari A., Akyol N. et al. The 1-month effects of topical betaxolol, dorzolamide and apraclonidine on ocular blood flow velocities in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica. 2001; 215 (5): 361–65. doi:10.1159/000050886
51. Galassi F., Sodi A., Renieri G., et al. Effects of timolol and dorzolamide on retrobulbar haemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica. 2002; 216 (2): 123–28. doi:10.1159/000048311
52. Januloviciene I., Harris A., Kagemann L., et al.A comparison of the effects of dorzolamide/timolol fixed combination versus letterpress in intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol. Scandinavica. 2004; 82 (6): 730–37. doi:10.1111/j.1600-0420.2004.00358.x
53. Fuchsjager-Mayrl G., Wally B., Rainer G., et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open-angle glaucoma and ocular hypertension. Br. J. Ophthalmol. 2005; 89 (10): 1293–7. doi:10.1136/bjo.2005.067637
54. Kaup M., Plange N., Niegel M., et al. Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Br. J. Ophthalmol. 2004; 88: 257–62.
55. Siesky B., Harris A., Cantor L., et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br. J. Ophthalmol. 2008; 92 (4): 500–4.
56. Kadam R.S., Jadhav G., Ogidigben M., Kompella U.B.Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow Drug. Metab. Dispos. 2011; 39 (9): 1529–37. doi: 10.1124/dmd.111.040055
57. Vogel A., Beck S., Schwenn O., et al.Reproducibility of measurement of ocular pulse amplitude and intraocular pressure using SmartLens. Ophthalmologe. 2001; 98 (10): 944–9. doi:10.1007/s003470170041
58. Josefsson A., Sigurdsson S.B., Bang K., Eysteinsson T. Dorzolamide induces vasodilatation in isolated pre-contracted bovine retinal arteries. Exp. Eye Res. 2004 Feb; 78 (2): 215–21. doi: 10.1016/j.exer.2003.11.010
59. Galose М., Elsaied Н., Macky Т., Fouad Р.Н.Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study. Indian J Ophthalmol. 2016; 64 (2): 127–31. doi:10.4103/0301-4738.179718
60. Manni G., Denis P., Chew P., et al.The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2 %/timolol 0.5 % in patients with open-angle glaucoma or ocular hypertension. Journal of glaucoma. 2009; 18 (4): 293–300. doi:10.1097/IJG.0b013e31818fb434
61. Pajic B., Pajic-Eggspuehler B., Hafliger I.O.Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary openangle glaucoma. Curr. Med. Res. Opin. 2010; 26 (9): 2213–19. doi:10.1185/03007995.2010.508702
62. Martinez A., Sanchez M.Predictive value of color Doppler imaging in a prospective study of visual fi eld progression in primary open-angle glaucoma. Acta Ophthalmol. Scand. 2005; 83(6): 716–23. doi:10.1111/j.1600-0420.2005.00567.x
63. Lovpache D.N., Kiseleva T.N., Ramazanova K.A. The use of Glauprost 0,005%, a prostaglandin analogue, in the treatment of patients with primary open angle glaucoma and its potentials for combined therapy. Russian ophthalmological journal. 2012; 5 (1): 42–5 (in Russian).
64. Kiseleva O.A., Iomdina E.N., Bessmertny A.M., et al. Evaluation of the effect of prostaglandin analogues and a carbonic anhydrase inhibitor/-blocker combination on the ocular blood flow in patients with primary open-angle glaucoma. Vestnik oftal'mologii. 2019; 135 (4): 70–7 (in Russian)]. doi:10.17116/oftalma201913504170
Review
For citations:
Malishevskaya T.N., Kiseleva T.N., Vlasova A.S., Eliseeva E.K. Impact of combination of local carbonic anhydrase inhibitors and beta-blockers on intraocular pressure, visual functions and eye hemodynamics in primary open-angle glaucoma. Russian Ophthalmological Journal. 2021;14(2):96-102. (In Russ.) https://doi.org/10.21516/2072-0076-2021-14-2-96-102
Views:
954
Email this article 